Anisomycin induces apoptosis of glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells via activation of mitogen-activated protein kinases p38 and JNK

Neoplasma

Volumn 60, Issue 1, 2013, Pages 101-110

  Liu, Y ^a   Ge, J ^a   Li, Q ^a   Gu, L ^a   Guo, X ^a   Ma, Z G ^a   Zhu, Y P ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Acute lymphoblastic leukemia (ALL); Anisomycin; Apoptosis; Glucocorticoid resistance; Jun N terminal kinase (JNK); P38 Mitogen Activated protein kinase (p38 MAPK)

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL) IMIDAZOLE; ANISOMYCIN; ANTHRA [1, 9 CD] PYRAZOL 6 (2H) ONE; APOPTOSIS REGULATORY PROTEIN; CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BIMEL; PROTEIN MCL 1; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DEXAMETHASONE; MESSENGER RNA; NUCLEIC ACID SYNTHESIS INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MTT ASSAY; WESTERN BLOTTING; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ANISOMYCIN; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NUCLEIC ACID SYNTHESIS INHIBITORS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84876007972     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2013_014     Document Type: Article

References (39)

1. GAYNON PS, CARREL AL. Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. Adv Exp Med Biol 1999; 457: 593-605. http://dx.doi.org/10.1007/978-1-4615-4811-9_66
2. SCHRAPPE M. Evolution of BFM trials for childhood ALL. Ann Hematol 2004; 83(suppl 1): S121-123.
3. KASPERS GJ, PIETERS R, KLUMPER E, DE WAAL FC, VEERMAN AJ. Glucocorticoid resistance in childhood leukemia. Leuk Lymphoma 1994; 13: 187-201.
4. MILLER L, WEBB MS, COPIK AJ, WANG Y, JOHNSON BH et al. p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol Endocrinol 2005; 19: 1569-1583. http://dx.doi.org/10.1210/me.2004-0528
5. TANAKA T, OKABE T, GONDO S, FUKUDA M, YAMAMOTO M, et al. Modification of glucocorticoid sensitivity by MAP kinase signaling pathways in glucocorticoid-induced T-cell apoptosis. Exp Hematol 2006; 34: 1542-1552. http://dx.doi.org/10.1016/j.exphem.2006.06.018
6. BARROS LF, YOUNG M, SAKLATVALA J, BALDWIN SA. Evidence of two mechanisms for the activation of the glucose transporter GLUT1 by anisomycin: p38(MAP kinase) activation and protein synthesis inhibition in mammalian cells. J Physiol 1997; 1; 504: 517-525.
7. YANG H, CHOI HJ, PARK SH, KIM JS, MOON Y. Macrophage inhibitory cytokine-1 (MIC-1) and subsequent urokinase-type plasminogen activator mediate cell death responses by ribotoxic anisomycin in HCT-116 colon cancer cells. Biochem Pharmacol 2009; 78: 1205-1213. http://dx.doi.org/10.1016/j.bcp.2009.06.012
8. ABAYASIRIWARDANA KS, BARBONE D, KIM KU, VIVO C, LEE KK, et al. Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim. Mol Cancer Ther 2007; 6: 2766-2776. http://dx.doi.org/10.1158/1535-7163.MCT-07-0278
9. PAP M, SZEBERENYI J. Involvement of proteolytic activation of protein kinase R in the apoptosis of PC12 pheochromocytoma cells. Cell Mol Neurobiol 2008; 28: 443-456. http://dx.doi.org/10.1007/s10571-007-9245-y
10. XIA S, LI Y, ROSEN EM, LATERRA J. Ribotoxic stress sensitizes glioblastoma cells to death receptor induced apoptosis: requirements for c-Jun NH2-Terminal Kinase and Bim. Mol Cancer Res 2007; 5: 783-792. http://dx.doi.org/10.1158/1541-7786.MCR-06-0433
11. MIZUNO R, OYA M, SHIOMI T, MARUMO K, OKADA Y, et al. Inhibition of MKP-1 expression potentiates JNK related apoptosis in renal cancer cells. J Urol 2004; 172: 723-727. http://dx.doi.org/10.1097/01.ju.0000124990.37563.00
12. CURTIN JF, COTTER TG. Anisomycin activates JNK and sensitizes DU145 prostate carcinoma cells to Fas mediated apoptosis. Br J Cancer 2002; 87: 1188-1194. http://dx.doi.org/10.1038/sj.bjc.6600612
13. HORI T, KONDO T, TABUCHI Y, TAKASAKI I, ZHAO QL, et al. Molecular mechanism of apoptosis and gene expressions in human lymphoma U937 cells treated with anisomycin. Chem Biol Interact 2008; 172: 125-140. http://dx.doi.org/10.1016/j.cbi.2007.12.003
14. ZAWYDIWSKI R, HARMON JM, THOMPSON EB. Glucocorticoid-resistant human acute lymphoblastic leukemic cell line with functional receptor. Cancer Res 1983; 43: 3865-3873.
15. ZHAO YN, GUO X, MA ZG, GU L, GE J, et al. Pro-apoptotic protein BIM in apoptosis of glucocorticoid-sensitive and-resistant acute lymphoblastic leukemia CEM cells. Med Oncol 2011; 28: 1609-1617. http://dx.doi.org/10.1007/s12032-010-9641-x
16. STAM RW, DEN BOER ML, SCHNEIDER P, DE BOER J, HAGELSTEIN J, et al. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood 2010; 115: 1018-1025. http://dx.doi.org/10.1182/blood-2009-02-205963
17. JIANG N, KOH GS, LIM JY, KHAM SK, ARIFFIN H, et al. BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia. Exp Hematol 2011; 39: 321-329. http://dx.doi.org/10.1016/j.exphem.2010.11.009
18. WANG Z, MALONE MH, HH H, MCCOLL KS, DISTELHORST CW. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein BIM in multiple models of glucocorticoid induced apoptosis. J Biol Chem 2003; 278: 23861-23867. http://dx.doi.org/10.1074/jbc.M301843200
19. ABRAMS MT, ROBERTSON NM, YOON K, WICKSTROM E. Inhibition of Glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA. J Biol Chem 2004; 279: 55809-55817. http://dx.doi.org/10.1074/jbc.M411767200
20. MERINO D, STRASSER A, BOUILLET P. Bim must be able to engage all pro-survival Bcl-2 family members for efficient tumor suppression. Oncogene 2011; doi: 10.1038/onc.2011.508. http://dx.doi.org/10.1038/onc.2011.508
21. GHIOTTO F, FAIS F, BRUNO S. BH3-only proteins: the death-puppeteer's wires. Cytometry A 2010; 77: 11-21.
22. QUINN BA, DASH R, AZAB B, SARKAR S, DAS SK, et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 2011; 20: 1397-1411. http://dx.doi.org/10.1517/13543784.2011.609167
23. STAVROVSKAYA AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000; 65: 95-106.
24. Kfir S, SIONOV RV, ZAFRIR E, ZILBERMAN Y, YEFENOF E. Staurosporine sensitizes T lymphoma cells to glucocorticoid-induced apoptosis: role of Nur77 and Bcl-2. Cell Cycle 2007; 6: 3086-3096. http://dx.doi.org/10.4161/cc.6.24.5023
25. PEPPER C, HOY T, BENTLEY P. Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are corre1ated with in vivo chemoresistance. Leuk Lymphoma 1998; 28: 355-361.
26. STRAUSFELD UP, HOWELL M, REMPEL R, MALLER JL, HUNT T, et al. Cip1 blocks the initiation of DNA replication in Xenopus extracts by inhibition of cyclin-dependent kinases. Curr Biol 1994; 4: 876-883. http://dx.doi.org/10.1016/S0960-9822(00)00196-2
27. SGAMBATO A, CITTADINI A, FARAGLIA B, WEINSTEIN IB. Multiple functions of p27 (Kip1) and its alterations in tumor cells: a review. J Cell Physiol 2000; 183: 18-27. http://dx.doi.org/10.1002/(SICI)1097-4652(200004)183:1<18::AIDJCP3>3.0.CO;2-S
28. HIRT A, SCHMID AM, JULMY F, SCHMITZ NM, LEIBUNDGUT K. Expression of cyclin A in childhood acute lymphoblastic leukemia cells reveals undisturbed G1-S phase transition and passage through the S phase. Leukemia 2009; 23: 414-417. http://dx.doi.org/10.1038/leu.2008.200
29. AREF S, MABED M, EL-SHERBINY M, SELIM T, METWALY A. Cyclin D1 expression in acute leukemia. Hematology 2006; 11: 31-34. http://dx.doi.org/10.1080/10245330500322321
30. WU SJ, DU X, CHEN YX, JIANG WL, ZHONG LY, et al. Relationship between cyclins and prognosis of acute leukemia. Ai Zheng 2003; 22: 852-855.
31. YUAN C, ZHANG YS, CHENG YN, XUE X, XU WF, et al. A112, a tamibarotene dimethylaminoethyl ester, may inhibit human leukemia cell growth more potently than tamibarotene. Leuk Lymphoma 2012; 53: 295-304. http://dx.doi.org/10.3109/10428194.2011.614707
32. JIRAWATNOTAI S, HU Y, MICHOWSKI W, ELIAS JE, BECKS L, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 2011; 474: 230-234. http://dx.doi.org/10.1038/nature10155
33. VERMA G, DATTA M. The critical role of JNK in the ER-mitochondrial crosstalk during apoptotic cell death. J Cell Physiol 2012; 227: 1791-1795. http://dx.doi.org/10.1002/jcp.22903
34. CUI J, WANG Q, WANG J, LV M, ZHU N, et al. Basal c-Jun NH2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells. Mol Cancer Ther 2009; 8: 3214-3222. http://dx.doi.org/10.1158/1535-7163.MCT-09-0408
35. LEUNG KT, LI KK, SUN SS, CHAN PK, OOI VE, et al. Activation of the JNK pathway promotes phosphorylation and degradation of BimEL--a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia. Carcinogenesis 2008; 29: 544-551.
36. CHIARINI F, DEL SOLE M, MONGIORGI S, GABOARDI GC, CAPPELLINI A, et al. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates Pglycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 2008; 22: 1106-1116. http://dx.doi.org/10.1038/leu.2008.79
37. LIU J, LIN A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res 2005; 15: 36-42. http://dx.doi.org/10.1038/sj.cr.7290262
38. ENSLEN H, BRANCHO DM, DAVIS RJ. Molecular determinants that mediate selective activation of p38 MAP kinase isoforms. EMBO J 2000; 19: 1301-1311. http://dx.doi.org/10.1093/emboj/19.6.1301
39. LU J, QUEARRY B, HARADA H. p38-MAP kinase activation followed by BIM induction is essential for glucocorticoidinduced apoptosis in lymphoblastic leukemia cells. FEBS Lett 2006; 580: 3539-3544. http://dx.doi.org/10.1016/j.febslet.2006.05.031